-+ 0.00%
-+ 0.00%
-+ 0.00%
Reported Sunday, Viking Therapeutics Reports 74% Of Subcutaneous VK2735 Participants Improved BMI Category Versus 15% On Placebo After 13 Weeks, With Improved Cardiometabolic Markers
Share
Listen to the news

VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks

VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending